Helios Biosciences presents a profile consistent with a mid-stage biotech in Phase 2 clinical development: strong scientific talent and leadership enthusiasm for AI, constrained by fragmented data infrastructure and the absence of enterprise-wide governance. Across 8 interviews spanning R&D, Clinical Operations, Regulatory Affairs, Finance, IT, and Commercial, the dominant theme is manual effort at every data boundary — CRO reconciliation, cross-functional report assembly, and undocumented handoffs.
The overall maturity score of 2.0/5.0 places the organization in the Developing tier. Every dimension scored below 2.5, indicating a consistent pre-integration data environment. The primary readiness gap is not talent or motivation — it is infrastructure. The relative strength of Organization & Culture (2.3) signals that internal conditions for change are present, and that structured investment will find a receptive organization.
This assessment was conducted using Perlustrate’s structured interview protocol, delivered via AI-facilitated stakeholder conversations. Each session followed a standardized question set covering data workflows, tooling, governance awareness, AI exposure, and strategic priorities. Responses were scored using a five-dimension maturity framework aligned to AI readiness prerequisites.
Maturity scores are assigned on a 1–5 scale per interview, per dimension, based on evidence in the transcript. Dimension scores represent the mean across all 8 completed sessions (40 individual scores). Pain points are extracted and deduplicated by theme; frequency reflects the number of distinct interviewees who surfaced each issue.
| Name | Role | Function | Duration |
|---|---|---|---|
| Dr. Margaret Tran | Chief Scientific Officer | C-Suite/VP | 12 min |
| James Okonkwo | Director of Clinical Operations | Operations | 11 min |
| Sandra Kowalski | Director of Regulatory Affairs | Regulatory/QA | 10 min |
| Dr. Kevin Park | Senior Research Scientist | Lab/R&D | 9 min |
| Priya Nair | Clinical Data Manager | Data/Analytics | 10 min |
| Rafael Mendez | IT Infrastructure Lead | IT/Engineering | 8 min |
| Linda Horvath | Finance Controller | Other | 9 min |
| Thomas Reyes | Commercial & Business Development Director | Commercial/BD | 8 min |
Issues below represent themes surfaced independently by multiple interviewees. Frequency indicates the number of participants who raised each issue without prompting. Verbatim quotes are drawn directly from interview transcripts.
Tools cited across all 8 interviews. The count badge indicates how many interviewees mentioned each tool. Faded chips represent single-person mentions.
Findings from this engagement are contextualized against current industry benchmarks and regulatory guidance relevant to life sciences AI readiness.
Recommendations are sequenced by dependency. AI capability deployment (Phase 3) requires data infrastructure and governance thresholds to be met in earlier phases. Each phase includes the minimum preconditions for advancing to the next.